Review of clinical trials using early acute intervention with oral triptans for migraine management

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 698-706

  Dowson, Andrew J ^a   Mathew, N T ^b   Pascual, J ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Houston Headache Clinic   (United States)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Almotriptan; Early treatment; Efficacy; Migraine; Tolerability; Triptans

Indexed keywords

ALMOTRIPTAN; CYCLOOXYGENASE 2 INHIBITOR; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ANALGESIA; BRAIN STEM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC EVALUATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY DYSFUNCTION; MIGRAINE; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ADMINISTRATION, ORAL; ANALGESICS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 33744517586     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00981.x     Document Type: Review

References (54)

1. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754-62.
2. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001; 10: 1831-45
3. Dodick DW. Triptan nonresponder studies: Implications for clinical practice. Headache 2005; 45: 156-62.
4. Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 2001; 15: 583-7.
5. Sheftell F, Tepper S. New paradigms in the recognition and treatment of migraine. Headache 2002; 42: 58-69.
6. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002; 42 (Suppl. 1): S10-7.
7. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol 2004; 55: 19-26.
8. Guidelines for controlled trials of drugs in migraine. First edition. International headache society committee on clinical trials in migraine. Cephalalgia 1991; 11: 1-12.
9. Gottschalk A, Smith DS. New concepts in acute pain therapy: Preemptive analgesia. Am Fam Physician 2001; 63: 1979-84.
10. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346: 257-70.
11. Cady RK, Schreiber CP, Farmer KU. Understanding the patient with migraine: The evolution from episodic headache to chronic neurologic disease. A proposed classification of patients with headache. Headache 2004; 44: 426-35.
12. Silberstein SD. Migraine. Lancet 2004; 363: 381-91.
13. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001; 89: 107-10.
14. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001; 358: 1668-75.
15. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671-7.
16. Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan aura study group. Neurology 1994; 44: 1587-92.
17. Dowson A, Ramphul-Gokulsing S, Klein K, Cox R, Wilkinson M, Gross M. Can oral 311c90, a novel 5HT1D agonist, prevent migraine headache when taken during an aura? Cephalalgia 1995; 15: 173.
18. Knoderer WR, Krusz JC. Pre-emptive almotriptan treatment for migraine. Cephalalgia 2004; 24: 796 (Abstract PC.19).
19. Krusz JC. Eletriptan and migraine re-emption. Cephalalgia 2004; 24: 796-7 (Abstract PC.20).
20. Aurora SK, Barrodale PM, McDonald SM, Burstein R. Preliminary evidence for improved efficacy when patients treat with sumatriptan 100 mg formulated with RT technology during visual aura in migraine. Cephalalgia 2005; 25: 928 (Abstract FO38).
21. Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000; 20: 122-6.
22. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study. Headache 2000; 40: 792-7.
23. Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin Ther 2000; 22: 1035-48.
24. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther 2005; 27: 1785-94.
25. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia 2004; 24: 925-33.
26. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (zomig, 311c90) in the acute treatment of migraine. An international study. Headache 1998; 38: 173-83.
27. Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004; 24: 918-24.
28. Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg odt in the acute treatment of migraine: Results of a large double-blind placebo- controlled trial. Curr Med Res Opin 2005; 21: 381-9.
29. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: A placebo-controlled study. Headache 2004; 44: 669-73.
30. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 2004; 20: 1465-72.
31. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache 2002; 42: 28-31.
32. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003; 43: 1075-9.
33. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004; 44: 318-22.
34. Brandes J, Kudrow D, Cady R, Tiseo P, Sun W, Sikes C. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia 2005; 25: 735-42.
35. Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc 2003; 78: 1214-22.
36. Silberstein SD. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 1995; 35: 387-96.
37. Kelman L. The premonitory symptoms (prodrome): A tertiary care study of 893 migraineurs. Headache 2004; 44: 865-72.
38. Lipton RB, Stewart WF, Cady R et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study. Headache 2000; 40: 783-91.
39. Giffin NJ, Ruggiero L, Lipton RB et al. Premonitory symptoms in migraine: An electronic diary study. Neurology 2003; 60: 935-40.
40. Foley KA, Cady R, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538-45.
41. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache 2003; 43: 36-44.
42. Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Efficacy and safety of rizatriptan versus standard care during long- term treatment for migraine. Rizatriptan multicenter study groups. Headache 1998; 38: 764-71.
43. Bomhof MA, Heywood J, Pradalier A, Enahoro H, Winter P, Hassani H. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan long-term study group. Cephalalgia 1998; 18: 33-7.
44. Cabarrocas X, Esbri R, Peris F, Ferrer P. Long-term efficacy and safety of oral almotriptan: Interim analysis of a 1-year open study. Headache 2001; 41: 57-62.
45. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002; 42 (Suppl. 2): S93-9.
46. Mathew N. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine attacks. Headache 2002; 42: 32-40.
47. Robbins L. Frequent triptan use: Observations on safety issues. Headache 2004; 44: 178-82.
48. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: A review of clinical data. Headache 2004; 44 (Suppl. 1): S20-30.
49. Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: Clinical features, pathogenesis and management. Drugs 2004; 64: 2503-14.
50. Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia 2002; 22: 491-512.
51. Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med 2005; 118 (Suppl. 1): 36S-44S.
52. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
53. Cady RK, Sheftell F, Lipton RB, Kwong WJ, O'Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther 2001; 23: 284-91.
54. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 2002; 42: 984-99.